• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Contineum Therapeutics Inc.

    2/3/26 4:32:15 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTNM alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001861550
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    CONTINEUM THERAPEUTIC, INC.
    SEC File Number
    001-42001
    Address of Issuer
    3565 General Atomics Court, Suite 200
    San Diego
    CALIFORNIA
    92121
    Phone
    8583335280
    Name of Person for Whose Account the Securities are To Be Sold
    DANIEL LORRAIN
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    417059964.602309917302/03/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common05/09/2017Restricted Stock UnitsIssuerCheckbox not checked417005/09/2017N/A

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    10b5-1 Sales for DANIEL LORRAIN
    3565 General Atomics Court, Suite 200
    San Diego � CA � 92121
    Common01/05/2026417043543.06
    10b5-1 Sales for DANIEL LORRAIN
    3565 General Atomics Court, Suite 200
    San Diego � CA � 92121
    Common12/23/2025417051009.11

    144: Remarks and Signature

    Remarks
    Date of Notice
    02/03/2026
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    09/23/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Daniel S. Lorrain

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CTNM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTNM

    DatePrice TargetRatingAnalyst
    1/8/2026$14.00Overweight → Equal-Weight
    Morgan Stanley
    11/13/2025$22.00Outperform
    Leerink Partners
    9/25/2025$20.00Outperform
    Leerink Partners
    6/20/2025Outperform
    William Blair
    10/22/2024$32.00Outperform
    Robert W. Baird
    More analyst ratings

    $CTNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Contineum Therapeutics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Contineum Therapeutics from Overweight to Equal-Weight and set a new price target of $14.00

    1/8/26 8:37:44 AM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Contineum Therapeutics with a new price target

    Leerink Partners initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $22.00

    11/13/25 9:09:54 AM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Contineum Therapeutics with a new price target

    Leerink Partners initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $20.00

    9/25/25 8:29:14 AM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTNM
    SEC Filings

    View All

    SEC Form 144 filed by Contineum Therapeutics Inc.

    144 - Contineum Therapeutics, Inc. (0001855175) (Subject)

    2/3/26 4:32:15 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Contineum Therapeutics Inc.

    SCHEDULE 13G/A - Contineum Therapeutics, Inc. (0001855175) (Subject)

    1/29/26 10:38:11 AM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Contineum Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)

    1/26/26 4:06:37 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by General Counsel and Corp Sec Healy John Stephen

    4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

    1/30/26 4:59:54 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Slover Peter T

    4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

    1/30/26 4:57:46 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by CEO and President Stengone Carmine N.

    4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

    1/30/26 4:56:17 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTNM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on January 26, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 23,000 shares of Class A common stock to one new non-executive employee under the Company's 2026 Employment Inducement Equity Incentive Plan. The award was granted as an inducement material to the new employee's employment with the Company in accordance with Nasdaq

    1/28/26 4:05:00 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the pricing of an upsized underwritten public offering of 7,346,938 shares of its Class A common stock at a public offering price of $12.25 per share. In addition, Contineum has granted the underwriters a 30-day option to purchase up to an additional 1,102,040 shares of its Class A common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts a

    12/11/25 10:24:00 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Contineum Therapeutics Announces Proposed $75.0 Million Public Offering

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the commencement of an underwritten public offering of $75.0 million of shares of its Class A common stock. In addition, Contineum intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its Class A common stock at the public offering price, less underwriting discounts and commissions. All securities in the proposed offering are to be sold by Contineum. The proposed offering is subject to mark

    12/11/25 4:05:00 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Contineum Therapeutics Inc.

    SC 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)

    11/14/24 4:38:16 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTNM
    Leadership Updates

    Live Leadership Updates

    View All

    Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

    4/28/25 4:05:00 PM ET
    $CTNM
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. "We are excited to welcome Diego to our board," commented Eef Schimmelpennink, Contineum's Chairperson. "He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr.

    3/17/25 4:05:00 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe

    1/6/25 8:00:00 AM ET
    $CTNM
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care